SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-172698
Filing Date
2023-06-22
Accepted
2023-06-22 17:20:01
Documents
14
Period of Report
2023-06-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d624436d8k.htm   iXBRL 8-K 28218
2 EX-99.1 d624436dex991.htm EX-99.1 27334
6 GRAPHIC g624436g0622094537604.jpg GRAPHIC 1795
  Complete submission text file 0001193125-23-172698.txt   193964

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA agle-20230622.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230622_lab.xml EX-101.LAB 18757
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230622_pre.xml EX-101.PRE 11706
8 EXTRACTED XBRL INSTANCE DOCUMENT d624436d8k_htm.xml XML 3462
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231034220
SIC: 2834 Pharmaceutical Preparations